ALRPRB.PFD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALRPRB.PFD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alere's Enterprise Value is $4,003.79 Mil. Alere's EBIT for the trailing twelve months (TTM) ended in Jun. 2017 was $-54.14 Mil. Therefore, Alere's EV-to-EBIT ratio for today is -73.96.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Alere's Enterprise Value is $4,003.79 Mil. Alere's EBITDA for the trailing twelve months (TTM) ended in Jun. 2017 was $212.53 Mil. Therefore, Alere's EV-to-EBITDA ratio for today is 18.84.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Alere's Enterprise Value is $4,003.79 Mil. Alere's Revenue for the trailing twelve months (TTM) ended in Jun. 2017 was $2,332.93 Mil. Therefore, Alere's EV-to-Revenue ratio for today is 1.72.
The historical data trend for Alere's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alere Annual Data | |||||||||||||||||||||
Trend | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | - | - | - | - | - |
Alere Quarterly Data | ||||||||||||||||||||
Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | |
Enterprise Value | Get a 7-Day Free Trial | - | - | - | - | - |
For the Diagnostics & Research subindustry, Alere's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Alere's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Alere's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Alere's Enterprise Value for the fiscal year that ended in Dec. 2016 is calculated as
Enterprise Value (A: Dec. 2016 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | + | 606.406 | + | 2865.426 | |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 85.434 | + | 4.615 | - | 567.291 |
= | 2,994.59 |
Alere's Enterprise Value for the quarter that ended in Jun. 2017 is calculated as
Enterprise Value (Q: Jun. 2017 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | + | 606.406 | + | 2820.775 | |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 86.671 | + | 5.163 | - | 491.849 |
= | 3,027.17 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alere (NYSE:ALRPRB.PFD) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Alere's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 4003.789 | / | -54.135 | |
= | -73.96 |
Alere's current Enterprise Value is $4,003.79 Mil.
Alere's EBIT for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-54.14 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Alere's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 4003.789 | / | 212.526 | |
= | 18.84 |
Alere's current Enterprise Value is $4,003.79 Mil.
Alere's EBITDA for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $212.53 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Alere's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 4003.789 | / | 2332.926 | |
= | 1.72 |
Alere's current Enterprise Value is $4,003.79 Mil.
Alere's Revenue for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,332.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Alere's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
John Bridgen | officer: Sr VP, Business Development | 51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453 |
Geoffrey S Ginsburg | director | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Renuka Uppaluri | officer: Senior VP, Global R&D | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Mark Gladwell | officer: Senior VP, Global Operations | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Gregg J Powers | director | C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110 |
Jonathan Wygant | officer: VP, Controller, CAO | 3750 TORREY VIEW COURT, SAN DIEGO X1 92130 |
Thomas Mckillop | director | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Melissa Guerdan | officer: SVP, Global Quality & Reg. | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Daniella Cramp | officer: Global Pres., Cardiometabolic | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Sanjay Malkani | officer: Global Pres., Toxicology | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
James Jr. Roosevelt | director | 51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453 |
Robert Bernard Hargadon | officer: SVP, Global Human Resources | 4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033 |
John F Levy | director | C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453 |
John Quelch | director | C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453 |
Carol R Goldberg | director | C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453 |
From GuruFocus
By gurufocus gurufocus • 11-16-2010
By Holly LaFon Holly LaFon • 09-17-2014
By Canadian Value Canadian Value • 03-06-2015
By Carmine Romano Carmine Romano • 12-21-2011
By Alberto Abaterusso Alberto Abaterusso • 10-23-2016
By Holly LaFon Holly LaFon • 11-14-2017
By Vera Yuan Vera Yuan • 11-21-2014
By Tiziano Frateschi Tiziano Frateschi • 02-26-2018
By Vera Yuan Vera Yuan • 03-17-2015
By Vera Yuan Vera Yuan • 11-21-2014
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.